• Explore /
  • Poster
  • / Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.

Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.

Abstract Video & Slides Poster

Authors

Hossein Borghaei

Hossein Borghaei

Fox Chase Cancer Center, Philadelphia, PA

Hossein Borghaei , Benjamin Besse , Aditya Bardia , Julien Mazieres , Sanjay Popat , Bincy Augustine , Anthony Michael D'amelio Jr., Daniel Barrios , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT04042701

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS1100)

DOI

10.1200/JCO.2020.38.15_suppl.TPS1100

Abstract #

TPS1100

Poster Bd #

185

Abstract Disclosures

Similar Posters

First Author: Fabrice Andre

First Author: Xuan Ge

First Author: Ian E. Krop

First Author: Guy Heinrich Maria Jerusalem